Initially, gadolinium-based contrast agents (GBCAs) have been considered as inert compounds without any potential to induce adverse side effects. Now, more than three decades after their introduction in clinical radiology, we know that GBCAs can be responsible for a broad range of adverse events including hypersensitivity reactions, nephropathy, and conditions due to their deposition in the organism [1].
